Trial Profile
5HT2A/C serotonin blockade in Parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 16 Nov 2007 Status changed from in progress to completed
- 01 Sep 2006 Status change
- 25 Oct 2005 New trial record.